Position statement on the appropriate usage of biologic therapies for asthma in South Africa.

Q3 Medicine
R N van Zyl-Smit, M Greenblatt, C Smith, N Singh, M Wong
{"title":"Position statement on the appropriate usage of biologic therapies for asthma in South Africa.","authors":"R N van Zyl-Smit, M Greenblatt, C Smith, N Singh, M Wong","doi":"10.7196/AJTCCM.2026.v32i1.4376","DOIUrl":null,"url":null,"abstract":"<p><p>Biologic therapies such as monoclonal antibodies are highly effective in reducing disease burden (exacerbations/corticosteroid usage/ hospitalisation) in patients with severe asthma. These medications are currently prohibitively expensive for widespread use compared with standard inhaled and oral therapy. They are indicated for patients with predominantly type 2-high inflammation. Judicious use of biologic therapies in the South African context is imperative given the country's limited healthcare resources. The prescription and clinical use of these therapies within the scope of the South African Health Products Regulatory Authority registered indications therefore require clear guidance and appropriate preparatory optimisation to ensure that the appropriate patients receive the correct medication within an acceptable time frame. Not all patients with difficult-to-treat, or nominally designated as severe, asthma require a biologic therapy in order to be optimally controlled. Simple attention to basic asthma therapeutic principles and treatment of comorbid disease by a clinician with a special interest in asthma may be all that is required. This position statement, written by senior clinicians from the South African Thoracic Society (SATS), is intended to supplement the SATS asthma treatment recommendation of 2021. It provides clear guidance on the appropriate assessment of patients being considered for biologic therapy and clarifies which background medication is required to initiate a biologic therapy in an evidence-based manner. A balanced consideration of side-effects, scientific evidence and cost is essential to prevent unjustified harm to patients by delaying or denying access to biologic therapy. A process to endorse biologic therapy has been created in parallel, and forms are available from SATS, along with registration in the severe asthma registry to support clinicians in appropriate assessment and justification for prescription.</p>","PeriodicalId":52847,"journal":{"name":"African Journal of Thoracic and Critical Care Medicine","volume":"32 1","pages":"e4376"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13277373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Thoracic and Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7196/AJTCCM.2026.v32i1.4376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Biologic therapies such as monoclonal antibodies are highly effective in reducing disease burden (exacerbations/corticosteroid usage/ hospitalisation) in patients with severe asthma. These medications are currently prohibitively expensive for widespread use compared with standard inhaled and oral therapy. They are indicated for patients with predominantly type 2-high inflammation. Judicious use of biologic therapies in the South African context is imperative given the country's limited healthcare resources. The prescription and clinical use of these therapies within the scope of the South African Health Products Regulatory Authority registered indications therefore require clear guidance and appropriate preparatory optimisation to ensure that the appropriate patients receive the correct medication within an acceptable time frame. Not all patients with difficult-to-treat, or nominally designated as severe, asthma require a biologic therapy in order to be optimally controlled. Simple attention to basic asthma therapeutic principles and treatment of comorbid disease by a clinician with a special interest in asthma may be all that is required. This position statement, written by senior clinicians from the South African Thoracic Society (SATS), is intended to supplement the SATS asthma treatment recommendation of 2021. It provides clear guidance on the appropriate assessment of patients being considered for biologic therapy and clarifies which background medication is required to initiate a biologic therapy in an evidence-based manner. A balanced consideration of side-effects, scientific evidence and cost is essential to prevent unjustified harm to patients by delaying or denying access to biologic therapy. A process to endorse biologic therapy has been created in parallel, and forms are available from SATS, along with registration in the severe asthma registry to support clinicians in appropriate assessment and justification for prescription.

关于南非适当使用生物疗法治疗哮喘的立场声明。
单克隆抗体等生物疗法在减轻严重哮喘患者的疾病负担(加重/皮质类固醇使用/住院)方面非常有效。与标准的吸入和口服治疗相比,这些药物目前的广泛使用价格过高。它们主要适用于2型高炎症患者。考虑到南非有限的医疗资源,明智地使用生物疗法是必要的。因此,在南非保健品管理局注册的适应症范围内,这些疗法的处方和临床使用需要明确的指导和适当的准备优化,以确保适当的患者在可接受的时间范围内获得正确的药物。并非所有难治性哮喘患者,或名义上被认定为严重哮喘的患者,都需要生物治疗才能得到最佳控制。对哮喘有特殊兴趣的临床医生对基本的哮喘治疗原则和合并症的治疗的简单关注可能是所需要的。这份立场声明由南非胸科学会(SATS)的高级临床医生撰写,旨在补充SATS 2021年哮喘治疗建议。它为考虑进行生物治疗的患者的适当评估提供了明确的指导,并阐明了以循证方式启动生物治疗需要哪些背景药物。必须平衡考虑副作用、科学证据和费用,以防止因延迟或拒绝获得生物治疗而对患者造成不合理的伤害。与此同时,批准生物治疗的程序也已创建,表格可从SATS获得,并在严重哮喘登记处注册,以支持临床医生进行适当的评估和处方证明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
African Journal of Thoracic and Critical Care Medicine
African Journal of Thoracic and Critical Care Medicine Medicine-Critical Care and Intensive Care Medicine
CiteScore
1.50
自引率
0.00%
发文量
30
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书